Corrections to “Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer”
Year: 2019
Type: erratum
Abstract: Ann Oncol 2018; 29: 139–144 (doi: 10.1093/annonc/mdx688) In the original article, author T. R. Pisanic II’s name was incorrectly spelt as ‘R. Pisanic II’. This has now been corrected. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancerAnnals of OncologyVol. 29Issue 1PreviewHypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC. Full-Text PDF Open Archive
Source: Annals of Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,250
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2942787861